This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Aging/ Geriatrics  • Neurology  • Cerebrovascular Disease  • Stroke  • Cardiovascular System  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Still an Open Question

Antonio Nicolucci, MD

JAMA. 2008;300(18):2180-2181. Published online November 9, 2008 (doi:10.1001/jama.2008.625).

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The use of aspirin for primary prevention of cardiovascular events in individuals with diabetes is widely recommended by existing guidelines, but the evidence supporting its efficacy is surprisingly scarce.¹ Recommendations seem based mainly on extrapolations from data from other high-risk groups, rather than on solid data derived from studies conducted specifically in patients with diabetes. Indeed, an increasing amount of evidence suggests that the efficacy of antiplatelet therapy in patients with diabetes may be lower than in individuals without diabetes.²

In this issue of JAMA, Ogawa and colleagues³ report the results of the JPAD trial (Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes), specifically designed to address the issue of antiplatelet therapy for the primary prevention of cardiovascular events in diabetes. The trial included 2539 patients with type 2 diabetes and without a history of atherosclerotic disease randomly assigned to low-dose aspirin (80-100 mg per . . . [Full Text of this Article]

Author Affiliations: Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes: A Randomized Controlled Trial
Hisao Ogawa, Masafumi Nakayama, Takeshi Morimoto, Shiro Uemura, Masao Kanauchi, Naofumi Doi, Hideaki Jinnouchi, Seigo Sugiyama, Yoshihiko Saito, and for the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators
JAMA. 2008;300(18):2134-2141.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Aspirin for the Primary Prevention of Cardiovascular Events: A systematic review and meta-analysis comparing patients with and without diabetes
Calvin et al.
Diabetes Care 2009;32:2300-2306.
ABSTRACT | FULL TEXT  

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
De Berardis et al.
BMJ 2009;339:b4531-b4531.
ABSTRACT | FULL TEXT  

The Role of Diabetes Educators in the Medical Home
O'Connor and Sperl-Hillen
Diabetes Spectr. 2009;22:124-126.
FULL TEXT  

Aspirin, Cardiovascular Disease, and Type 2 Diabetes
JWatch General 2008;2008:3-3.
FULL TEXT